AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28381796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine without valproic acid
Number of subjects: 12
Study 24787263 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐Child Interaction Therapy (PCIT)
Number of subjects: 46
Study 24787263 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 46
Study 25073598 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous PRP therapy combined with a rehabilitation program
Number of subjects: 28
Study 25073598 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation program only
Number of subjects: 28
Study 25073598 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous PRP therapy
Number of subjects: 28
Study 22173851 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine alone (2.0 mg/kg)
Number of subjects: 28
Study 22173851 — intervention group
Group type: COMPARATOR
Intervention: Alcohol alone (0.6 g/kg)
Number of subjects: 28
Study 22173851 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol/caffeine
Number of subjects: 28
Study 20718814 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg)
Number of subjects: 0
Study 17701048 — intervention group
Group type: COMPARATOR
Intervention: Self-contained breathing apparatus with compressed air (BA-A)
Number of subjects: 12
Study 17701048 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox with self-contained breathing apparatus (BA-H)
Number of subjects: 12
Study 15970291 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate plus dienogest
Number of subjects: 80
Study 15970291 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 80
Study 15970291 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (genistein)
Number of subjects: 80
Study 15970291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15970291 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Raloxifene, Estradiol valerate plus dienogest, Soy isoflavones)
Number of subjects: 80
Study 11920977 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 66
Study 11920977 — intervention group
Group type: COMPARATOR
Intervention: Matched control sample
Number of subjects: 66
Study 9468233 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg taken at bedtime
Number of subjects: 7
Study 9468233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7892497 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance (MR) spectroscopy in patients with probable Alzheimer disease (AD)
Number of subjects: 114
Study 7892497 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance (MR) spectroscopy in patients with other dementias (OD)
Number of subjects: 114
Study 7892497 — intervention group
Group type: EXPERIMENTAL
Intervention: MI/NAA ratio in patients with probable Alzheimer disease (AD)
Number of subjects: 114
Study 7892497 — intervention group
Group type: EXPERIMENTAL
Intervention: MI/creatine ratio in patients with other dementias (OD)
Number of subjects: 114
Study 2642313 — intervention group
Group type: EXPERIMENTAL
Intervention: Otis internal urethrotomy
Number of subjects: 185
Study 2642313 — intervention group
Group type: COMPARATOR
Intervention: 2-day urethral catheter dilation
Number of subjects: 185
Study 2642313 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene coated resectoscope sheath
Number of subjects: 185
Study 2642313 — intervention group
Group type: COMPARATOR
Intervention: Uninsulated metal resectoscope sheath
Number of subjects: 185
Study 7035030 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 X 10(8) killed armadillo-derived M. leprae
Number of subjects: 0
Study 7035030 — intervention group
Group type: COMPARATOR
Intervention: Live BCG and killed M. leprae (mixture)
Number of subjects: 0
Study 7035030 — intervention group
Group type: COMPARATOR
Intervention: BCG
Number of subjects: 0
Study 7035030 — intervention group
Group type: EXPERIMENTAL
Intervention: Armadillo-derived M. leprae
Number of subjects: 0
Study 31539605 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARE arm
Number of subjects: 986
Study 31539605 — intervention group
Group type: COMPARATOR
Intervention: Advance directive-only arm
Number of subjects: 986
Study 31539605 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparisons
Number of subjects: 986
Study 28634822 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (1800 mg/day)
Number of subjects: 100
Study 28634822 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 26445565 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish coffee (3 mg·kg(‐1) BW of caffeine)
Number of subjects: 20
Study 26445565 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated Turkish coffee
Number of subjects: 20
Study 23393144 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up by a clinical nurse specialist (CNS)
Number of subjects: 68
Study 23393144 — intervention group
Group type: COMPARATOR
Intervention: Follow-up by a medical doctor (MD)
Number of subjects: 68
Study 21710137 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional materials describing how to rate child ADHD symptoms
Number of subjects: 100
Study 21710137 — intervention group
Group type: COMPARATOR
Intervention: No instructional materials
Number of subjects: 100
Study 21710137 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional materials
Number of subjects: 100
Study 19427428 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 15603
Study 19427428 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 15603
Study 19427428 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 15603
Study 19427428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15603
Study 19425467 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyconutritional supplement
Number of subjects: 62
Study 19425467 — intervention group
Group type: COMPARATOR
Intervention: Control substance
Number of subjects: 62
Study 15745291 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive continuous infusion by gravitational force (Group 1)
Number of subjects: 147
Study 15745291 — intervention group
Group type: COMPARATOR
Intervention: Manually controlled pressure bag infusion at about 40 mmHg (Group 2)
Number of subjects: 147
Study 12227872 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (Triaz 6% special gel), applied twice daily for 14 days
Number of subjects: 20
Study 12227872 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (1% clindamycin phosphate in Cleocin-T lotion), applied twice daily for 14 days
Number of subjects: 20
Study 9231932 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) 60 mg daily
Number of subjects: 415
Study 9231932 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 40 mg daily
Number of subjects: 415
Study 8381298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal fibre intake
Number of subjects: 147
Study 8381298 — intervention group
Group type: COMPARATOR
Intervention: Polyunsaturated fat intake
Number of subjects: 147
Study 8381298 — intervention group
Group type: COMPARATOR
Intervention: Total fibre intake
Number of subjects: 147
Study 3307390 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral iv infusion of a 900 mosmol amino acid-glucose solution (2 L/day) for 21 days
Number of subjects: 28
Study 3307390 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 28
Study 11680575 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ribavirin/day (group A)
Number of subjects: 69
Study 11680575 — intervention group
Group type: COMPARATOR
Intervention: 1,000-1,200 mg ribavirin/day (group B)
Number of subjects: 69
Study 29150328 — intervention group
Group type: EXPERIMENTAL
Intervention: AAFP 500mg daily plus 4mg methylprednisolone BID
Number of subjects: 53
Study 29150328 — intervention group
Group type: COMPARATOR
Intervention: OAA 1000mg daily plus 5mg prednisone BID
Number of subjects: 53
Study 26458911 — intervention group
Group type: EXPERIMENTAL
Intervention: CogniPlus training (20 sessions, twice a week)
Number of subjects: 80
Study 26458911 — intervention group
Group type: COMPARATOR
Intervention: Physical training (30 min daily for 10 weeks)
Number of subjects: 80
Study 25378467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone with digoxin
Number of subjects: 1619
Study 25378467 — intervention group
Group type: COMPARATOR
Intervention: Placebo with digoxin
Number of subjects: 1619
Study 25378467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone without digoxin
Number of subjects: 1619
Study 25378467 — intervention group
Group type: COMPARATOR
Intervention: Placebo without digoxin
Number of subjects: 1619
Study 19686283 — intervention group
Group type: EXPERIMENTAL
Intervention: CNC titanium frameworks
Number of subjects: 126
Study 19686283 — intervention group
Group type: COMPARATOR
Intervention: Gold-alloy castings
Number of subjects: 126
Study 19688282 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy-led lifestyle intervention
Number of subjects: 0
Study 19688282 — intervention group
Group type: COMPARATOR
Intervention: Routine general practitioner's care
Number of subjects: 0
Study 18791687 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Gy gamma radiation exposure
Number of subjects: 0
Study 16034044 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment for 2 years
Number of subjects: 564
Study 12119513 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant healing
Number of subjects: 400
Study 12119513 — intervention group
Group type: COMPARATOR
Intervention: Control (no distant healing)
Number of subjects: 400
Study 10514156 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert system based on the transtheoretical model of behaviour change, incorporating three sessions using an expert system computer program and three class lessons.
Number of subjects: 8352
Study 10514156 — intervention group
Group type: COMPARATOR
Intervention: Health education as part of the English national curriculum (Control group).
Number of subjects: 8352
Study 8610286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardial closure with PHB patch
Number of subjects: 50
Study 8610286 — intervention group
Group type: COMPARATOR
Intervention: No pericardial patch (control group)
Number of subjects: 50
Study 1782306 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg b.d.
Number of subjects: 0
Study 1782306 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg nocte
Number of subjects: 0
Study 1782306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1782306 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (20 mg) b.d.
Number of subjects: 0
Study 6109989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium bromide (muscle relaxation)
Number of subjects: 50
Study 6109989 — intervention group
Group type: COMPARATOR
Intervention: Control (no muscle relaxation)
Number of subjects: 50
Study 31277176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 104
Study 31277176 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 29216868 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personal diabetes care for 6 years
Number of subjects: 1381
Study 26445178 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (3 times a day for >5 minutes each time from postoperative day 1 to the first day of food intake)
Number of subjects: 48
Study 26445178 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 48
Study 24306134 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg for males, 0.75 g/kg for females)
Number of subjects: 30
Study 24306134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24306134 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 30
Study 21706245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 316
Study 19683086 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose given 5 years post-primary vaccination (Group Y5)
Number of subjects: 559
Study 19683086 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose given 10 years post-primary vaccination (Group Y10)
Number of subjects: 559
Study 17464746 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM assay
Number of subjects: 24
Study 17464746 — intervention group
Group type: EXPERIMENTAL
Intervention: Human clinical studies
Number of subjects: 24
Study 28079517 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of candesartan and rosuvastatin
Number of subjects: 40
Study 28079517 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of candesartan and rosuvastatin
Number of subjects: 40
Study 12132492 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 0
Study 12132492 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 0
Study 12132492 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 10065905 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (neuroleptics, major tranquillizers)
Number of subjects: 0
Study 10065905 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepines
Number of subjects: 0
Study 7909402 — intervention group
Group type: EXPERIMENTAL
Intervention: Best 'drug' therapy (class I or class III antiarrhythmic therapy)
Number of subjects: 34
Study 7909402 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 34
Study 7909402 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 34
Study 3048121 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 34
Study 3048121 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 34
Study 3048121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31385858 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation of the Eustachian tube
Number of subjects: 47
Study 27856288 — intervention group
Group type: EXPERIMENTAL
Intervention: aCT1 gel formulation plus conventional standard of care protocols
Number of subjects: 0
Study 27856288 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 0
Study 25588457 — intervention group
Group type: EXPERIMENTAL
Intervention: Single hyaluronate injection (HI group)
Number of subjects: 29
Study 25588457 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (CM group)
Number of subjects: 29
Study 24037998 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 15
Study 24037998 — intervention group
Group type: COMPARATOR
Intervention: No bosentan (control)
Number of subjects: 15
Study 22359979 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once a week or Ibandronate 50 mg once a month
Number of subjects: 341
Study 19252043 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced brief interpersonal psychotherapy (IPT-B)
Number of subjects: 53
Study 19252043 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 53
Study 19252043 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced IPT-B
Number of subjects: 53
Study 17127494 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dimensional (4D) ultrasound
Number of subjects: 63
Study 15641878 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (plus placebo)
Number of subjects: 30
Study 15641878 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (plus placebo)
Number of subjects: 30
Study 15641878 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of risperidone and paroxetine
Number of subjects: 30
Study 10944645 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized counseling aimed at limiting fat intake to 30% to 35% of daily energy, with a saturated:monounsaturated:polyunsaturated fatty acid ratio of 1:1:1 and cholesterol intake of less than 200 mg/d (n = 540)
Number of subjects: 496
Study 10944645 — intervention group
Group type: COMPARATOR
Intervention: Usual health education (control group, n = 522)
Number of subjects: 496
Study 8628561 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% DfNa eye drops three times daily
Number of subjects: 17
Study 8628561 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 17
Study 1481685 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAAs) supplementation (7.5-12 g) during exercise
Number of subjects: 0
Study 1481685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6377249 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 249
Study 6377249 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 249
Study 31047687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue‐plasminogen activator (IV tPA)
Number of subjects: 41
Study 31047687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 41
Study 31047687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment decisions (IV tPA and MT)
Number of subjects: 41
Study 31047687 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion‐Weighted‐Imaging‐Alberta‐Stroke‐Program‐EArly‐CT‐Score (DWI‐ASPECTS)
Number of subjects: 41
Study 31047687 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT willingness
Number of subjects: 41
Study 27529575 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home telerehabilitation (TELE)
Number of subjects: 205
Study 27529575 — intervention group
Group type: COMPARATOR
Intervention: Usual face-to-face home visit (STD) rehabilitation
Number of subjects: 205
Study 25808292 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF pMDI with VHC
Number of subjects: 60
Study 25808292 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF pMDI without VHC
Number of subjects: 60
Study 25808292 — intervention group
Group type: COMPARATOR
Intervention: Free combination of BDP pMDI and FF pMDI
Number of subjects: 60
Study 25808292 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF pMDI in adolescents
Number of subjects: 60
Study 23380000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 440
Study 23380000 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance Improvement Initiative
Number of subjects: 440
Study 21725513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine with saline solution before endoscopic biliary drainage (n=64)
Number of subjects: 102
Study 21725513 — intervention group
Group type: COMPARATOR
Intervention: Saline solution alone before endoscopic biliary drainage (n=38)
Number of subjects: 102
Study 21725513 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional dopamine administration during the postdrainage phase (n=31)
Number of subjects: 102
Study 21725513 — intervention group
Group type: COMPARATOR
Intervention: No additional dopamine administration during the postdrainage phase (n=33)
Number of subjects: 102
Study 19520360 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (1 mg)
Number of subjects: 16
Study 19520360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18025315 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with large volume and low positive pressure (n = 64)
Number of subjects: 127
Study 18025315 — intervention group
Group type: COMPARATOR
Intervention: Spray (n = 63)
Number of subjects: 127
Study 18025315 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 127
Study 15025747 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg daily for 6 days
Number of subjects: 18
Study 15025747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12423708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day) added to ongoing statin therapy
Number of subjects: 769
Study 12423708 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to ongoing statin therapy
Number of subjects: 769
Study 12423708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus statin
Number of subjects: 769
Study 12423708 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus statin
Number of subjects: 769
Study 10890228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaglobin (5 ml/kg body weight intravenously each day for 5 days)
Number of subjects: 100
Study 10890228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% glucose solution with 1% human albumin, 5 ml/kg body weight intravenously each day for 5 days)
Number of subjects: 100
Study 8688309 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENX), 75 anti-Xa IU/kg (n = 100)
Number of subjects: 201
Study 8688309 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH), 50 IU/kg (n = 101)
Number of subjects: 201
Study 8688309 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENX), 75 anti-Xa IU/kg
Number of subjects: 201
Study 8688309 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 201
Study 8688309 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENX)
Number of subjects: 201
Study 1707570 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with nitrosomethylurea, vincristine, and peplomycin
Number of subjects: 129
Study 1707570 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with nitrosomethylurea, vincristine, and bleomycetin
Number of subjects: 129
Study 1707570 — intervention group
Group type: COMPARATOR
Intervention: Single-agent treatment with dacarbazine
Number of subjects: 129
Study 7049819 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilazep 300 mg/die
Number of subjects: 50
Study 7049819 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 30 mg/die
Number of subjects: 50
Study 3971651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside alone (group 1; n = 10)
Number of subjects: 20
Study 3971651 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside-trimethaphan mixture (group 2; n = 10)
Number of subjects: 20